A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis
Latest Information Update: 02 Mar 2025
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Perennial allergic rhinitis
- Focus Registrational; Therapeutic Use
- Acronyms PREPARED-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 31 Jan 2025 Planned End Date changed from 1 May 2026 to 1 Feb 2027.
- 31 Jan 2025 Planned primary completion date changed from 1 May 2025 to 1 Oct 2025.
- 28 May 2024 Planned primary completion date changed from 30 May 2025 to 1 May 2025.